Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for stratifying diabetic patients

A technology for type 1 diabetes and patients, applied in chemical instruments and methods, metabolic diseases, pharmaceutical formulations, etc.

Pending Publication Date: 2022-07-12
IMCYSE
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, there is no information on the role of, and patient response to, the use of immunogenic peptides containing insulin T-cell epitopes linked to oxidoreductase motifs in T1D patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for stratifying diabetic patients
  • Method for stratifying diabetic patients
  • Method for stratifying diabetic patients

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0269] Example 1: Binding of immunogenic peptides comprising insulin MHCII T cell epitopes and oxidoreductase motifs to soluble DRB1*0301 or DRB1*0401 recombinant MHC II proteins.

[0270] To test the binding of peptides comprising MHC class II T-cell epitopes and oxidoreductase motifs from the proinsulin region C20_A1, a soluble phase competition assay was performed with increasing concentrations of HCPYCVRSLQPLALEGSLQKRG (SEQ ID. NO: 25) The peptide with HCPYCSLQPLALEGSLQKRG (SEQ ID. NO. 26) competed with the labeled control peptide (high affinity binder; biotinylated) for binding to soluble DRBI*0301 or DRB1*0401 recombinant human MHC II protein. As the binding approaches equilibrium (18 hours), the peptide-MHC II complex is captured and separated from the unbound reagent. The captured peptide-MHCII complex was detected by time-resolved fluorescence (Eu 3+ Streptavidin) was quantified, and the data were processed and plotted to determine the dose-dependent binding properti...

Embodiment 2

[0271] Example 2: Ability of immunogenic peptides comprising insulin MHCII T cell epitopes and oxidoreductase motifs to prime and expand CD4+ T cells from various insulin-dependent diabetic patients.

[0272] Naive CD4+ T cells from different type 1 diabetes (T1D) patients were tested for reactivity to the peptide defined by the sequence HCPYCVRSLQPLALEGSLQKRG. T1D patients were first tested for HLA DRB1 typing (see Table 1).

[0273] Table 1: HLA DRB1 typing of T1D patients tested.

[0274]

[0275] HLA typing is performed using methods known in the art, eg as reported in Mack et al., 2009, Tissue Antigens. 2009 Jan;73(1):17-32.

[0276] Blood samples were then processed and naive CD4+ T cells were purified by magnetic separation techniques. Peptide priming and amplification of these were tested using peptide-preloaded autologous dendritic cells (monocyte-derived DCs differentiated in the presence of GM-CSF and IL-4 followed by maturation with TNF-α) as antigen-presentin...

Embodiment 3

[0278] Example 3: Phase Ib clinical trial with an immunogenic peptide with the sequence HCPYCSLQPLALEGSLQKRG in T1D patients.

[0279] The safety, clinical efficacy, and induction of immune responses of an immunogenic peptide with the sequence HCPYCSLQPLALEGSLQKRG were evaluated in a Phase Ib clinical trial in recent-onset (≤6 months) adult T1D patients. In this dose-escalation, placebo-controlled study, patients received four biweekly subcutaneous injections of one of the three tested doses or matching placebo. The peptides were injected with alum as an adjuvant. Patients were followed for 6 months to evaluate the safety of the peptides and the induction of immune responses.

[0280] The main inclusion criteria are:

[0281] -BMI 1728kg / m 2 of men and women between the ages of 18 and 30;

[0282] - Preliminary diagnosis of type 1 diabetes according to ADA / WHO criteria within the past 6 months;

[0283] - Insulin requirements determined by the investigator;

[0284] - HL...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a method of predicting the response of a type 1 diabetes patient to a treatment with an immunogenic peptide comprising an insulin MHC II T cell epitope and an oxidoreductase motif, comprising determining the MHC class II HLA haplotype of the patient.

Description

Background technique [0001] Several strategies have been described to prevent the development of unwanted immune responses against antigens. WO2008 / 017517 describes a new strategy using peptides containing MHC class II T cell epitopes and oxidoreductase motifs for a given antigenic protein. These peptides convert CD4+ T cells into a cell type with cytolytic properties, termed cytolytic CD4+ T cells. These cells are capable of killing by triggering apoptosis those antigen presenting cells (APCs) that present the antigens from which the peptides are obtained. WO2008 / 017517 shows this concept for allergy and autoimmune diseases such as type 1 diabetes. Here, insulin acts as an autoantigen [0002] Antigen-specific cytolytic cells are further described in more detail in WO2009101207 and Carlier et al. (2012) Plos one 7, 10e45366. [0003] WO2016059236 also discloses modified peptides in which additional histidines are present near the oxidoreductase motif. [0004] WO20181624...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/00A61P3/10C07K14/62
CPCA61K39/0008A61P3/10A61K2039/545A61K2039/55505C07K14/62C07K2319/00C12N9/0004G01N33/56977G01N2333/70539G01N2800/52
Inventor 文森特·卡利尔
Owner IMCYSE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com